Editorials - page 16

Intensive glucose control and cardiovascular disease in type 2 diabetes – should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials

Peter Gæde

Pol Arch Intern Med. 2008, Vol. 118, No. 11: 619-621 / DOI: 10.20452/pamw.504

Should physicians initiate β‑blocker therapy in patients undergoing non‑cardiac surgery? Insights from the POISE trial

Pablo Alonso‑Coello, Pilar Paniagua, Ryszard Mizera, Philip J. Devereaux

Pol Arch Intern Med. 2008, Vol. 118, No. 11: 616-618 / DOI: 10.20452/pamw.502

Should all patients with chronic kidney disease take a statin? A commentary to a meta-analysis of randomized control trials

Eberhard Ritz

Pol Arch Intern Med. 2008, Vol. 118, No. 10: 541-542 / DOI: 10.20452/pamw.482

European guidance for the diagnosis and management of osteoporosis in postmenopausal women – what is the current message for clinical practice?

John A. Kanis, Jean-Yves Reginster

Pol Arch Intern Med. 2008, Vol. 118, No. 10: 538-540 / DOI: 10.20452/pamw.480

Venous thromboembolism in hospitalized patients – are we doing enough to prevent it? Commentary to the ENDORSE trial

Frederick A. Anderson

Pol Arch Intern Med. 2008, Vol. 118, No. 10: 536-537 / DOI: 10.20452/pamw.478

European guidance for osteoporosis: an American perspective

Michael R. McClung

Pol Arch Intern Med. 2008, Vol. 118, No. 9: 462-463 / DOI: 10.20452/pamw.456

Are long-acting β2‑agonists safe in the treatment of asthma?

Stephen T. Holgate

Pol Arch Intern Med. 2008, Vol. 118, No. 9: 460-461 / DOI: 10.20452/pamw.454

New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective

Daniel J. Wallace

Pol Arch Intern Med. 2008, Vol. 118, No. 7-8: 402-403 / DOI: 10.20452/pamw.432

Should every patient with diabetes receive a statin?

Ewa Dembowski, Michael H. Davidson

Pol Arch Intern Med. 2008, Vol. 118, No. 7-8: 398-401 / DOI: 10.20452/pamw.430

2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice?

Carolina C. Gonzaga, David A. Calhoun

Pol Arch Intern Med. 2008, Vol. 118, No. 7-8: 396-397 / DOI: 10.20452/pamw.428

Angiotensin‑converting enzyme inhibitors and angiotensin‑receptor blockers in preventive cardiology: which drug to use and what to expect in light of the ONTARGET trial

John A. Cairns

Pol Arch Intern Med. 2008, Vol. 118, No. 6: 335-338 / DOI: 10.20452/pamw.406

The low glycemic index diet: new way of eating for all?

Jennie Brand‑Miller, Kate Marsh

Pol Arch Intern Med. 2008, Vol. 118, No. 6: 332-334 / DOI: 10.20452/pamw.404

The Androgen Excess Society guidelines on glucose intolerance in the polycystic ovary syndrome: what do they mean and what should we do?

John E. Nestler

Pol Arch Intern Med. 2008, Vol. 118, No. 5: 264-266 / DOI: 10.20452/pamw.382

Venous leg ulcers: where does surgery fit in?

Charles N. McCollum

Pol Arch Intern Med. 2008, Vol. 118, No. 5: 262-263 / DOI: 10.20452/pamw.380

Managing painful neuropathy in diabetes

Edward B. Jude, Koshy Jacob

Pol Arch Intern Med. 2008, Vol. 118, No. 5: 260-261 / DOI: 10.20452/pamw.378

American guidelines for the management of spontaneous intracerebral hemorrhage in adults: European perspective

Thorsten Steiner, Eric Jüttler

Pol Arch Intern Med. 2008, Vol. 118, No. 4: 181-182 / DOI: 10.20452/pamw.354

2007 update of the Global Initiative for Asthma management and prevention: what’s new?

Paul M. O’Byrne

Pol Arch Intern Med. 2008, Vol. 118, No. 4: 179-180 / DOI: 10.20452/pamw.352

New American College of Chest Physicians guidelines on ediastinal staging and management of stage IIIA‑N2 non‑small cell lung ancer: a European perspective

Kurt G. Tournoy, Jan P. van Meerbeeck

Pol Arch Intern Med. 2008, Vol. 118, No. 4: 175-178 / DOI: 10.20452/pamw.350

What is the best pharmacological treatment to prevent exacerbation of chronic obstructive pulmonary disease?

Bartolome R. Celli

Pol Arch Intern Med. 2008, Vol. 118, No. 4: 172-174 / DOI: 10.20452/pamw.348

New statement of the European Society of Cardiology on diagnosing diastolic heart failure: what are the key messages

M. Louis Handoko, Walter J. Paulus

Pol Arch Intern Med. 2008, Vol. 118, No. 3: 100-101 / DOI: 10.20452/pamw.324

previousof 18next

Impact Factor 2023

3.8

Quartile in the category

Q1

IC value for 2022

217.18

Ministry of Education and Science score

200
Average times from:
submission to 1st decision, 2 days
submission to first reviews, 24 days
acceptance to online first publication, 5 days
acceptance to final publication, 45 days

Current manuscript acceptance rate: 27%
The journal is co-financed from the state budget under the "Development of scientific journals" program of the Ministry of Education and Science in the years 2022-2024. Read more